Population-level interest in anti-rheumatic drugs in the COVID-19 era: insights from Google Trends
- PMID: 33130946
- PMCID: PMC7603411
- DOI: 10.1007/s10067-020-05490-w
Population-level interest in anti-rheumatic drugs in the COVID-19 era: insights from Google Trends
Abstract
Introduction/objective: The general public may utilize online information through search engines for implications and risks of some anti-rheumatic drugs. These drugs have been used in the management of coronavirus disease 2019 (COVID-19) and associated inflammatory sequelae or cytokine storm of infection. Therefore, the objective of this study was to investigate the population-level interest in anti-rheumatic drugs during the COVID-19 era, by analyzing changes in Google search frequency data.
Method: To obtain the relative search volume (RSV) of anti-rheumatic drugs, we queried Google Trends for 78 search terms representing non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, antigout agents, conventional disease-modifying anti-rheumatic drugs (DMARDs), immunosuppressants, biologics, and Janus kinase (JAK) inhibitors within the USA. Three 8-week periods in 2020 (March 15-May 9), (May 10-July 4), and (July 5-August 29) representing the initial- and short-term periods were compared to overlapping periods of the preceding 3 years (2017-2019).
Results: We found statistically significant increases in RSV for colchicine, hydroxychloroquine, tocilizumab (and its brand name-Actemra), and anakinra, and statistically significant decreases among brand names of immunosuppressive agents (i.e., mycophenolate mofetil, azathioprine, cyclophosphamide, tacrolimus, cyclosporine) during both the initial- and short-term COVID-19 periods as compared to overlapping periods of the preceding 3 years.
Conclusion: There were significant increases in RSV of colchicine, hydroxychloroquine, tocilizumab, and anakinra during both initial- and short-term COVID-19 periods when compared to overlapping periods of the preceding 3 years reflecting a heightened level of information-seeking on these drugs during the pandemic. Rheumatologists should address this increase in informational demand. Further research assessing medium- and long-term interest in anti-rheumatic drugs is required to increase our knowledge on this new pandemic. Key Points •This study was aimed to investigate the population-level interest in anti-rheumatic drugs in the COVID-19 era, by analyzing changes in Google search frequency data. •Significant increases were seen in relative searches for colchicine, hydroxychloroquine, tocilizumab, and anakinra during both initial and short-term COVID-19 periods when compared to similar periods of 2017-2019 reflecting a heightened level of information-seeking on these drugs during the pandemic. •Rheumatologists should address this increase in informational demand for colchicine, hydroxychloroquine, tocilizumab, and anakinra.
Keywords: Anakinra; Colchicine; Google search; Hydroxychloroquine; Internet; Tocilizumab.
Conflict of interest statement
SK received congress travel, accommodation, and participation fee support (12th Anatolian Rheumatology Days) from Abbvie. The other authors have no conflict of interest in this study.
References
-
- World Health Organization announces COVID-19 outbreak a pandemic. https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus.... Accessed 12 Sept 2020
-
- World Health Organization. https://covid19.who.int/. Accessed 12 Sept 2020
-
- Montero F, Martínez-Barrio J, Serrano-Benavente B, González T, Rivera J, Molina Collada J, Castrejón I, Álvaro-Gracia J. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int. 2020;40:1593–1598. doi: 10.1007/s00296-020-04676-4. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
